Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast Cancer

Marija Balic; Gabriel Rinnerthaler; Rupert Bartsch

doi:10.1159/000518696

Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast Cancer

Marija Balic
, Gabriel Rinnerthaler (Co-Autor/-in)
, Rupert Bartsch

Universitätsklinik für Innere Medizin 3 - Hämatologie, internistische Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum

Publikation: Beitrag in Fachzeitschrift › Übersichtsarbeit › Begutachtung

4 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	664-676
Fachzeitschrift	Breast care (Basel, Switzerland)
Jahrgang	16
Ausgabenummer	6
DOIs	https://doi.org/10.1159/000518696
Publikationsstatus	Veröffentlicht - 2021

Zugriff auf Dokument

10.1159/000518696

Dieses zitieren

@article{4f03b122caa247e69cea272efecfe47a,

title = "Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast Cancer",

keywords = "PROGESTERONE-RECEPTOR, ESTROGEN-RECEPTOR, FINAL ANALYSIS, JOINT ANALYSIS, DOUBLE-BLIND, FOLLOW-UP, TRASTUZUMAB, CHEMOTHERAPY, NEUTROPENIA, EFFICACY",

author = "Marija Balic and Gabriel Rinnerthaler and Rupert Bartsch",

note = "Rinnerthaler: Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute – Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University, Salzburg, Austria",

year = "2021",

doi = "10.1159/000518696",

language = "English",

volume = "16",

pages = "664--676",

journal = "Breast care (Basel, Switzerland)",

issn = "1661-3791",

publisher = "Karger ",

number = "6",

}

TY - JOUR

T1 - Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast Cancer

AU - Balic, Marija

AU - Rinnerthaler, Gabriel

AU - Bartsch, Rupert

N1 - Rinnerthaler: Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute – Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University, Salzburg, Austria

PY - 2021

Y1 - 2021

KW - PROGESTERONE-RECEPTOR

KW - ESTROGEN-RECEPTOR

KW - FINAL ANALYSIS

KW - JOINT ANALYSIS

KW - DOUBLE-BLIND

KW - FOLLOW-UP

KW - TRASTUZUMAB

KW - CHEMOTHERAPY

KW - NEUTROPENIA

KW - EFFICACY

U2 - 10.1159/000518696

DO - 10.1159/000518696

M3 - Review article

C2 - 35082573

SN - 1661-3791

VL - 16

SP - 664

EP - 676

JO - Breast care (Basel, Switzerland)

JF - Breast care (Basel, Switzerland)

IS - 6

ER -